Multidrug-resistant tuberculosis in Victoria: a 10-year review

Caroline J Lavender, Lynne K Brown and Paul D R Johnson
Med J Aust 2009; 191 (6): 315-318.
  • Caroline J Lavender1
  • Lynne K Brown2
  • Paul D R Johnson3

  • 1 Mycobacterium Reference Laboratory, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC.
  • 2 TB Control Section, Victorian Department of Health, Melbourne, VIC.
  • 3 Austin Health, Melbourne, VIC.


We thank James Fielding, Victorian Department of Health, for assistance with the ethics application, and Dr Janet Fyfe and Aina Sievers, Victorian Mycobacterium Reference Laboratory, for additional details on cases. We also thank staff in the School of Public Health, in particular Dr Priscilla Robinson, and students of the Master of Public Health program, at La Trobe University for helpful discussions.

Competing interests:

None identified.

  • 1. National Tuberculosis Advisory Committee. Multi-drug resistant tuberculosis: information paper (October 2007). Commun Dis Intell 2007; 31: 406-409.
  • 2. World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva: WHO, 2008. (accessed Mar 2008).
  • 3. Lumb R, Bastian I, Gilpin C, et al. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2006: a report of the Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell 2008; 32: 12-17.
  • 4. Victorian Government Department of Human Services. Management, control and prevention of tuberculosis: guidelines for health care providers. Melbourne: DHS, 2002.
  • 5. Australian Education International. International student enrolments in Australia — 1994 to 2006. Canberra: AEI, 2008. (accessed Sep 2008).
  • 6. Australian Government Department of Immigration and Citizenship. Settler arrivals 1996–97 to 2006–07 — Australia, states and territories. Canberra: DIAC, 2007.
  • 7. Australian Government Department of Immigration and Citizenship. Supplement to form 1163i. Complete country listings for the health assessment matrix. Canberra: Commonwealth of Australia, 2009. (accessed Aug 2009).
  • 8. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000; 55: 962-963.
  • 9. Brown H. WHO identifies drug-resistant tuberculosis “hotspots”. Lancet 2004; 363: 951.
  • 10. Moore-Gillon J. Multidrug-resistant tuberculosis: this is the cost. Ann N Y Acad Sci 2001; 953: 233-240.
  • 11. Menzies D. Screening immigrants to Canada for tuberculosis: chest radiography or tuberculin skin testing? CMAJ 2003; 169: 1035-1036.
  • 12. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 1850-1859.
  • 13. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789.
  • 14. Coker R, van Weezenbeek KL. Mandatory screening and treatment of immigrants for latent tuberculosis in the USA: just restraint? Lancet Infect Dis 2001; 1: 270-276.
  • 15. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.